CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 29, 2016--
Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced it will participate in
two investor conferences in February:
-
Canaccord Genuity Rare Disease, BioPharma One-on-One Day on Tuesday,
Feb. 2, 2016 in New York, NY.
-
Leerink Partners Global Healthcare Conference on Feb. 10 – 11, 2016 in
New York, NY.
Roger Pomerantz, M.D., Chairman, President and CEO of Seres, will
participate in a question and answer session on the first day of the
Leerink Partners Global Healthcare Conference. The session will be
available under the Investors and Media section of Seres’ website at www.serestherapeutics.com.
A replay of the session will become available approximately one hour
after the event and will be archived on the site for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a leading microbiome therapeutics platform
company developing a novel class of biological drugs that are designed
to treat disease by restoring the function of a dysbiotic microbiome
characterized by an increased presence of pathogenic bacterial species,
where the natural state of bacterial diversity is imbalanced. Seres’
most advanced program, SER-109, has successfully completed a Phase 1b/2
study demonstrating a clinical benefit in patients with recurring Clostridium
difficile infection (CDI) and is currently being evaluated in a
Phase 2 study in recurring CDI. The FDA has granted SER-109 Orphan Drug,
as well as Breakthrough Therapy, designations. Seres’ second clinical
candidate, SER-287, is being evaluated in a Phase 1b study in patients
with mild-to-moderate ulcerative colitis (UC).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160129005817/en/
Source: Seres Therapeutics, Inc.
IR Contact:
Seres Therapeutics
Carlo
Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate
Communications
Ctanzi@serestherapeutics.com
or
PR
Contact:
Ten Bridge Communications
Dan Quinn,
781-475-7974
Dan@tenbridgecommunications.com